| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 103.35B | 87.43B |
| Cost of Revenue | 32.69B | 53.54B |
| Gross Profit | 70.66B | 33.88B |
| Operating Expenses | 29.27B | 17.7B |
| Research and Development | 254.54M | 1.88B |
| Selling, General & Administrative Expenses | 29.02B | 14.69B |
| Selling & Marketing Expenses | 6.04B | 3.74B |
| General & Administrative Expenses | 22.98B | 10.95B |
| Other Expenses | 0 | -1.13B |
| Operating Income | 40.87B | 16.18B |
| Total Other Income/Expenses Net | -16.87B | 408.39M |
| Income Before Tax | 23.99B | 16.59B |
| Income Tax | 4.58B | 3.62B |
| Net Income | 19.13B | 12.82B |
| Basic EPS | 47.75 | 32 |
| EPS Diluted | 47.68 | 32 |
| Basic Average Shares | 400.59M | 400.59M |
| Diluted Average Shares | 401.17M | 400.59M |
| EBITDA | 28.09B | 20.27B |
Mankind Pharma Limited
MANKIND.NS
NSE
2350.5INR36.55 (1.58%)
MANKIND.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 80.12B | 67.35B |
| Net Income | 19.13B | 12.82B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | 0 | 0 |
| Retained Earnings | 99.19B | 80.12B |
| Other Distributions | 19.07B | 12.77B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 31.39B | 30.76B |
| Annual Depreciation | 3.98B | 3.26B |
| Capital Expenditure | -3.82B | -8.32B |
| Net PPE | 31.23B | 35.82B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 0 | -4.2M |
| Goodwill (Previous Year) | 200.23M | 204.42M |
| Goodwill | 200.23M | 200.23M |